利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

53 条记录 (耗时 0.035 秒)

    Combinations for the treatment of diseases involving cell proliferation
    2.
    发明授权
    Combinations for the treatment of diseases involving cell proliferation 有权
    用于治疗涉及细胞增殖的疾病的组合

    公开(公告)号：US08591895B2

    公开(公告)日：2013-11-26

    申请号：US13342507

    申请日：2012-01-03

    申请人： Gerd Munzert ,  Martin Steegmaier ,  Anke Baum

    发明人： Gerd Munzert ,  Martin Steegmaier ,  Anke Baum

    IPC分类号： A61K39/395 ,  A61K33/24 ,  A61K31/535 ,  A01N43/50 ,  A01N43/00

    CPC分类号： A61K31/4985 ,  A61K31/435 ,  A61K31/4409 ,  A61K31/519

    摘要： Disclosed are pharmaceutical compositions for the treatment of diseases which involve cell proliferation. Also disclosed are methods for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given herein and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

    摘要翻译： 公开了用于治疗涉及细胞增殖的疾病的药物组合物。 还公开了治疗所述疾病的方法，包括共同给予式（I）的化合物1，其中基团L，R 1，R 2，R 3，R 4和R 5具有本文给出的含义和有效量的 活性化合物2和/或以放射疗法共同治疗，以提供添加剂和协同效应的比例，以及组合使用式（I）化合物1和有效量的活性化合物2和/ 或放射治疗用于制造相应的药物组合制剂。

    Quinazoline derivatives and pharmaceutical compositions containing them
    10.
    发明授权
    Quinazoline derivatives and pharmaceutical compositions containing them 有权
    喹唑啉衍生物和含有它们的药物组合物

    公开(公告)号：US08586608B2

    公开(公告)日：2013-11-19

    申请号：US12563340

    申请日：2009-09-21

    申请人： Frank Himmelsbach ,  Elke Langkopf ,  Stefan Blech ,  Birgit Jung ,  Anke Baum ,  Flavio Solca

    发明人： Frank Himmelsbach ,  Elke Langkopf ,  Stefan Blech ,  Birgit Jung ,  Anke Baum ,  Flavio Solca

    IPC分类号： A61K31/47 ,  A01N43/42

    CPC分类号： C07D405/12 ,  C07D239/94

    摘要： A compound of general formula I wherein: Ra is a benzyl, 1-phenylethyl, or 3-chloro-4-fluorophenyl group; Rb is a dimethylamino, N-methyl-N-ethylamino, diethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetra-hydrofuran-3-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetra-hydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino group; and Rc is a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group, or a tautomer, stereoisomer, or salt thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation thereof.

    摘要翻译： 通式I的化合物，其中：R a是苄基，1-苯乙基或3-氯-4-氟苯基; Rb是二甲基氨基，N-甲基-N-乙基氨基，二乙基氨基，N-甲基-N-异丙基氨基，N-甲基-N-环丙基氨基，N-甲基-N-（2-甲氧基乙基）氨基，N-乙基-N- （2-甲氧基乙基）氨基，双（2-甲氧基乙基）氨基，吗啉代，N-甲基-N-（四氢呋喃-3-基）氨基，N-甲基-N-（四氢呋喃-2-基甲基）氨基，N - 甲基-N-（四氢呋喃-3-基甲基）氨基，N-甲基-N-（四氢吡喃-4-基）氨基或N-甲基-N-（四氢吡喃-4-基甲基）氨基; Rc为环丙基甲氧基，环丁氧基，环戊氧基，四氢呋喃-3-基氧基，四氢呋喃-2-基甲氧基，四氢呋喃-3-基甲氧基，四氢吡喃-4-基氧基或四氢吡喃-4-基甲氧基，或互变异构体，立体异构体或盐 特别是其具有有价值的药理学特性的无机或有机酸或碱的生理上可接受的盐，特别是对由酪氨酸激酶介导的信号转导的抑制作用，它们在治疗疾病尤其是肿瘤疾病和肺疾病中的用途 和气道及其制备。